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Abstract
Background: We hypothesized that pretreatment serum levels of insulin and other serum markers would predict
Progression-free survival (PFS), defined as time to castration-resistant progression or death, in metastatic androgen-
dependent prostate cancer (mADPC).
Methods: Serum samples from treatment-naïve men participating in a randomized phase 3 trial of ADT +/- chemotherapy
were retrospectively analyzed using multiplex assays for insulin and multiple other soluble factors. Cox proportional hazards
regression models were used to identify associations between individual factor levels and PFS.
Results: Sixty six patients were evaluable (median age = 72 years; median prostate surface antigen [PSA] = 31.5 ng/mL;
Caucasian = 86 %; Gleason score ≥8 = 77 %). In the univariable analysis, higher insulin (HR = 0.81 [0.67, 0.98] p = 0.
03) and C-peptide (HR = 0.62 [0.39, 1.00]; p = 0.05) levels were associated with a longer PFS, while higher Hepatocyte
Growth Factor (HGF; HR = 1.63 [1.06, 2.51] p = 0.03) and Osteopontin (OPN; HR = 1.56 [1.13, 2.15]; p = 0.01) levels
were associated with a shorter PFS. In multivariable analysis, insulin below 2.1 (ln scale; HR = 2.55 [1.24, 5.23];
p = 0.011) and HGF above 8.9 (ln scale; HR = 2.67 [1.08, 3.70]; p = 0.027) levels were associated with longer PFS,
while adjusted by OPN, C-peptide, trial therapy and metastatic volume. Four distinct risk groups were identified by
counting the number of risk factors (RF) including low insulin, high HGF, high OPN levels, and low C-peptide
levels (0, 1, 2, and 3). Median PFS was 9.8, 2.0, 1.6, and 0.7 years for each, respectively (p < 0.001).
Conclusion: Pretreatment serum insulin, HGF, OPN, and C-peptide levels can predict PFS in men with mADPC treated
with ADT. Risk groups based on these factors are superior predictors of PFS than each marker alone.
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Background
Metastatic prostate cancer is initially highly treatable
using androgen-deprivation therapy (ADT) that depletes
gonadal sources of systemic testosterone [1]. Over time,
however, these cancers eventually lose their responsive-
ness to ADT and become castration-resistant. While the
median time to castration-resistant progression is 18 to
24 months, the duration of response is quite variable,
with some men developing castration-resistant disease
within 6 months of initiating ADT, while others remain
responsive for 5 years or more. This variability reflects
the underlying biologic heterogeneity of prostate cancer
progression, a complex multi-genic process occurring
principally in bone, the preferred site of prostate cancer
metastases [2]. Multiple signaling pathways provide
crosstalk between the epithelial and the stromal com-
partments within the bone microenvironment to en-
hance tumor growth, including the androgen receptor,
tyrosine-kinases, and immune surveillance [1]. The tran-
sition from androgen-dependent to castration-resistant
disease is a clinically notable event, as it signals the
imminent lethal potential of advanced disease. Death
from metastatic prostate cancer typically occurs within
24 to 48 months of developing castration-resistance.
At present, prognostic markers for patients newly di-
agnosed with metastatic androgen-dependent prostate
cancer (mADPC) remain relatively limited. The most re-
liable and significant predictors of overall survival are
the absolute prostate specific antigen (PSA) nadir after
6–8 months of ADT initiation and the time to PSA pro-
gression after the nadir [3, 4]. An obvious disadvantage
of these variables is that they are not available when pa-
tients are initially diagnosed and treated. While several
studies have associated pretreatment variables with the
development of castration resistance and overall survival,
none has yet become routinely incorporated into clinical
practice or clinical research, in part due to the small
retrospective nature of the data and/or lack of prospect-
ive validation of individual biomarkers. For example,
pretreatment PSA kinetics (but not absolute PSA values)
and number of circulating tumor cells have been shown
to predict time to castration-resistant progression in pa-
tients with advanced disease [5, 6], and serum alkaline
phosphatase levels, serum PSA to acid phosphatase ratio,
and extent of disease (number of bone lesions and/or in-
volvement of viscera) with overall survival [7–9]. Thus,
as knowledge about the mechanisms of prostate cancer
progression evolves, there is continued interest in devel-
oping novel candidate biomarkers that reflect the patho-
physiology of the disease.
Of particular interest to our group has been the role of
insulin metabolism and hyperinsulinemia in prostate
cancer progression. In cells that express both the insulin
receptor (IR) and insulin-like growth factor-1 receptor
(IGF-1R), hybrid IGF-1R/IR receptors are formed, and
these hybrid receptors are activated by insulin-like
growth factor-1 (IGF-1) as well as likely insulin [10]. In
a murine model, diet induced hyperinsulinemia has been
shown to accelerate the growth of prostate cancer. Mice
on a high carbohydrate-high fat diet had higher levels of
serum IGF-1 and their tumors showed higher levels of
activated Akt and higher insulin receptor levels than tu-
mors from mice on a low carbohydrate-high fat diet
[11]. Prostate cancer cell lines cultured in the presence
of insulin induce steroidogenesis and increase their
expression of PSA [12]. In addition, evidence from
population-based screening cohorts has demonstrated
that both insulin and IGF-1 levels correlate more closely
than PSA levels with the risk of developing prostate can-
cer [11, 13]. Given evidence showing prostate cancer re-
sponsiveness to insulin in mouse models [11] and insulin
receptor expression by human prostate cancer cells [14], it
is possible that hyperinsulinemia facilitates progression to
castration-resistant prostate cancer (CRPC) [15].
With this background, the goal of the current study was
to explore whether pre-treatment levels of insulin and
other biomarker candidates would predict Progression-
free survival (PFS) defined as time to castration-resistant
progression or death in men with mADPC initiated on
ADT. The role of insulin metabolism in CRPC progres-
sion deserves further study because of the increasing
prevalence of hyperinsulinemia in the population at risk
to develop prostate cancer, and because of the availability
of therapies (such as dual small molecule inhibitors of
IGF-1R and IR) to target insulin and IGF-1 pathways in
patients with advanced disease [16].
In the present study we retrospectively analyzed
banked serum samples from a randomized phase 3 study
evaluating whether chemotherapy given in addition to
standard androgen deprivation would delay the appear-
ance of castration-resistant disease. Study participants
were randomized and time to emergence of CRPC, the
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primary endpoint, was not statistically different between
groups, suggesting that the addition of chemotherapy to
ADT does not confer a clinical benefit in this population
[17]. The primary endpoint of the current study was to
determine if the baseline insulin levels were associated
with PFS. Secondary endpoints included the identifica-
tion of other possible biomarkers for PFS.
Methods
Patients
Details regarding the eligibility criteria of included pa-
tients are published elsewhere [17]. In brief, 286 men
with treatment-naïve metastatic prostate cancer were
randomized to ADT alone or ADT plus ketoconazole
and doxorubicin alternating with vinblastine and estra-
mustine for three cycles. Castration-resistance was de-
fined as disease progression with a serum testosterone
level of <50 ng/dL. Both the primary endpoint of time to
CRPC and the secondary endpoint of overall survival
(OS) were not statistically different between the treat-
ment arms [17]. For this reason, patients from both
treatment arms were combined in the present analysis.
All subjects provided informed written consent to par-
ticipate in the phase III trial. A waiver of informed con-
sent and authorization was previously approved to
establish a historical tissue and data repository (proto-
col number LAB10-0335). Under this protocol, a modi-
fied honest broker system [18] was established to
collect and provide coded health information to re-
search investigators in a manner where it would not be
reasonably possible for the investigators or others to
identify the corresponding patients/specimens directly
or indirectly. In this system, the honest broker holds
the key to the patient’s identity and will in no circum-
stances release the codes. An additional waiver of in-
formed consent and authorization was requested to
allow laboratory testing to be performed as outlined in
this protocol (protocol number LAB 10-0528), which
was approved by the Institutional Review Board at MD
Anderson. Serum analysis was approved by the Institu-
tional Review Board at MD Anderson. The original
phase III clinical study (internal MD Anderson trial ID:
DM95-231) anteceded the introduction of the Clinical-
Trials.gov website for trial registration in year 2000 and
thus does not carry a trial registration number.
Serum cytokine analysis
Non-fasting, pre-treatment serum samples from 66 pa-
tients were available for analysis. Circulating levels of
soluble factors were measured using Searchlight immu-
noassays (Aushon BioSystems, Billerica, MA). Briefly,
samples were incubated for 1 h on the array plates that
were pre-spotted with capture antibodies specific for
each protein biomarker. Plates were decanted and
washed four times before adding a cocktail of biotinyl-
ated detection antibodies to each well. After incubating
with detection antibodies for 30 min, plates were
washed four times and incubated for 30 min with
streptavidin-horseradish peroxidase conjugate. All incu-
bations were done at room temperature with shaking at
200 rpm. Plates were again washed before adding a che-
moluminescent substrate. The plates were immediately
imaged using the Aushon Signature Plus CCD Imaging
System©, and data was analyzed using Aushon PROarray
Analyst Software©.
Statistical analysis
PFS was defined as time from ADT treatment start to
CRPC or death, whichever came first. CRPC was evi-
denced by any of the following: symptomatic or radio-
graphic progression, increasing PSA, or receipt of any
new systemic therapy with serum levels of testosterone
<50 ng/ml [17]. Patients alive and free of progression at
their last follow-up were censored on that date. Defin-
ition for disease volume was based on the original study,
for our analysis patients were adjusted in high-volume
metastasis (HVM, ≥3 bone lesions or visceral involve-
ment) and low volume metastasis (LVM, <3 bone lesions
and local/nodal involvement with or without prior de-
finitive local therapy) [17]. Dates of PFS and death were
independently confirmed by chart review by three of the
authors (FD, JCA, PGC).
The Kaplan-Meier product limit method [19] was used
to estimate the median PFS for each clinical/demographic
factor and for each of the serum markers. Univariable Cox
proportional hazards regression models [20] were used to
identify any association with each of the variables and
PFS. Serum markers were transformed using the natural
log scale. If the transformed marker showed a skewed dis-
tribution to the right, the natural log of the serum marker
was used for analysis. For each factor, medians, HRs, their
95 % confidence interval (CI), and hazard ratio p-values
are presented in tables. Kaplan-Meier curves are presented
for any significant factors associated with PFS. For serum
marker measures, the univariable Cox proportional haz-
ards regression p-value is based on the continuous meas-
ure, but for the Kaplan-Meier curves they are split at the
median or using the values found using CART for presen-
tation as described below. Multivariable Cox proportional
hazards regression [20] adjusted by trial therapy and me-
tastasis volume was used to model all the statistically sig-
nificant variables in the univariable setting. Biomarkers
were included as continuous values unless cumulative
Martingale residual plots indicated transformation by cut-
point indicator variables were more appropriate in the
multivariable regression [21, 22]. CART analysis was used
to identify biomarker cut points for the PFS analysis. The
CART model included the biomarkers found statistically
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significant in the univariable analysis. Biomarkers with no
identified cut point in the multivariable model were
explored in a univariate CART analysis to determine
whether any cut point could be identified since this is a
first exploratory examination of these markers. Finally,
we identified the number of risk factors for each patient
by identifying whether a patient was above or below a
cut point for each significant biomarker. If no cut point
was found, then the biomarker was split by the median
for the purposes of identifying whether a patient was
on the risky side of the biomarker. Each patient was
then given a score from 0 to the total number of signifi-
cant biomarkers counting up how many of the markers
the patient had on the poorer-performing direction. All
comparisons used a two-sided significance level of 0.05
for this exploratory study to identify markers to be con-
firmed in a future study. A total of 55 biomarkers were
tested, so only markers that are significant at <0.001 using
Bonferroni correction are considered statistically signifi-
cant without future confirmation. Statistical analysis was
performed using STATA/SE version 13.1 statistical soft-
ware (Stata Corp. LP, College Station, TX).
Results
Patients
Table 1 presents the patient characteristics of the popu-
lation included in the analysis. The median age was
72 years and median PSA of was 31.5 ng/mL. Patients
were primarily white (86 %), overweight/obese (59 %),
without diabetes (94 %), with Zubrod performance status
1 or 2 (53 %), with high volume metastatic disease
(HVM, 53 %), a Gleason score ≥8 (77 %), and were
treated with ADT on trial (52 %).
Progression-free survival
Figure 1a presents the PFS for the group. The median PFS
was 1.8 years (95 % CI: 1.4–2.6 years). Figure 1b presents
the PFS curves by metastasis volume. Table 2 shows the
univariable cox proportional hazard regression models for
PFS. There were a total of 66/66 (100 %) progressions and/
or deaths. Only metastatic volume, Insulin, C-peptide,
Hepatocyte Growth Factor (HGF), and Osteopontin
(OPN) were significantly associated with PFS. Patients with
HVM were nearly three times as likely to develop castra-
tion-resistance compared to those with LVM (HR =
2.93 [1.70–5.05]; p = <0.001). Higher levels of Insulin
(HR = 0.81, 95 % CI: 0.67–0.98; p = 0.03) and C-
peptide (HR = 0.62, 95 % CI: 0.39–1.00; p = 0.05) were
associated with longer PFS. Conversely, higher levels
of HGF (HR = 1.63 [1.06–2.51]; p = 0.03) and OPN
(HR = 1.56 [1.13–2.15]; p = 0.01) were associated with
shorter PFS. Figure 2a-e presents the PFS curves for
each of these factors.
The multivariable CART model adjusted by treatment
and metastatic volume found a cutpoint for insulin only.
However, CART models including the biomarkers only
identified cutpoints for HGF and OPN. Cumulative Martin-
gale Residual assessment confirmed that these 3 markers
need to be included as dichotomous variables in the multi-
variate model to avoid bias. Table 3 presents the multivari-
able model results for PFS. When accounting for metastasis
volume, treatment, HGF, OPN, and C-Peptide having Insu-
lin levels below 2.1 (ln scale) more than doubled the risk of
progression or death (HR = 2.55 [1.24, 5.23]; p = 0.011).
Similarly, patients with HGF levels higher than 8.9 (ln scale)
had double the risk of progression or death (HR = 2.00
[1.08, 3.70]; p = 0.027). OPN and C-peptide were not sig-
nificant at the 0.05 level, but removing them changes the
Table 1 Patient characteristics
Characteristic Number Percent
All Patients 66 100
Age (years) Median (min, max) 72 (57, 93)





Underweight (<18.5) 1 1.5
Normal (18.5–24.9) 13 19.7
Overweight (25.0–29.9) 25 37.9
Obese 14 21.2

















ADT + Chemo 31 47.0
Not Available 1 1.5
ADT Androgen Deprivation Therapy, Chemo Chemotherapy
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significance of the others, so all markers remain together in
the same model. Figure 2a-d represents a risk stratification
model for progression using insulin (ln scale below 2.1),
HGF (ln scale above 11.9), and OPN (ln scale above 8.9),
and C-peptide (below the median = 3309.607). No patient
had all 4 risk factors. Thus, four risk groups with distinct
PFS curves (p = 0.004) were identified, as outlined in Fig. 2e:
0, 1, 2, or 3 risk factors with corresponding median PFS of
9.8 , 2.0, 1.6, and 0.7 years, respectively.
Discussion
The emergence of castration-resistance signals the lethal
potential of metastatic prostate cancer and is considered
to be a biologically and clinically significant event. Con-
siderable research effort is currently directed towards
the development of novel therapy strategies that delay
the onset of castration-resistance and/or overcome
mechanisms of castration-resistance [1]. Thus, the
current inability to predict when an individual patient
will develop castration-resistant disease confounds clin-
ical practice, challenges personalization of therapy, and fos-
ters uncertainty for both patients and physicians. Based on
this, there is a great need to identify pre-treatment prog-
nostic markers for the development of castration-resistant
disease with the goal to anticipate this event and direct vul-
nerable patients towards novel therapy strategies.
In this study, we initially sought to test a biologically
derived hypothesis that baseline insulin levels with or
without other markers would predict time to castration-
resistant progression in patients with advanced prostate
cancer treated with ADT. By multivariable analysis, we
found that higher insulin levels were associated with
Fig. 1 Progression-free survival (a) for all the patients and (b) by Metastasis Volume
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longer time to castration-resistant progression in our co-
hort. Because higher insulin levels are indicative of
metabolic syndrome and both have previously been as-
sociated with increased risk of developing and dying
from prostate cancer, we initially predicted that higher
insulin levels would also correlate with shorter time to
castration-resistant progression. In support of this,
Flanagan et al. recently found that the presence of meta-
bolic syndrome (defined by multiple criteria of which
hyperinsulinemia is one) is a risk factor for the earlier
development of castration-resistant progression in pa-
tients with metastatic androgen-dependent prostate can-
cer treated with ADT [23]. However, in their study,
insulin levels were not specifically evaluated, and more
importantly, they showed that higher glucose levels (i.e.
by inference lower relative insulin secretion), was associ-
ated with shorter time to castration resistance. This is
actually in keeping with our findings. Although our
retrospective data set did not permit characterization of
metabolic syndrome in individual patients, our findings
suggest complex interactions between insulin and energy
metabolism versus prostate cancer development, and
prostate cancer progression. It is very important to view
our seemingly contrary results in view of the published
literature, including some recent new studies. Previous
work has proposed hyperinsulinemia as a risk factor for
lethal clinical prostate cancer [24]. However, it is import-
ant to note that this association was only observed in
men with newly diagnosed localized prostate cancer, not
men with more advanced metastatic setting, as included
in our study. A more recent meta-analysis of more than
10,000 men with prostate cancer established a positive
correlation of IGF-1 and 2 with prostate cancer develop-
ment, but not progression of metastatic disease [25].
Perhaps the differential role of insulin and IGF-1 in
prostate cancer development vs. castration resistance is
one of the underlying reasons for the failure of cixutu-
mumab (a monoclonal antibody that targets IGF-1R) to
improve time to castration resistance in metastatic pros-
tate cancer [26] (an almost identical cohort to our
patient cohort).
Furthermore, a large study of the European Prospect-
ive Investigation into Cancer and Nutrition (EPIC)
showed that men with diabetes had a 26 % lower risk of
prostate cancer [27]. Consequently, only metformin has
been associated with reduced risk for prostate cancer,
while oral hypoglycemia that directly affect insulin, have
not [28]. The postulated anti-tumor effects of metformin
are complex, but they appear not to be insulin mediated,
but possibly through inhibition of cancer stem cells [29].
Obviously, the fact that blood samples from our study
were not uniformly collected with respect to fasting versus
non-fasting may have confounded our results. It would
have been potentially beneficial to correlate insulin levels
with other parameters of insulin resistance to further cor-
roborate our findings. However, such markers were not
part of the tested biomarker panel and lack of sample
availability for further testing means this option should be
pursued in an independent cohort validation. Despite the
fact that we don’t have certainty on the fasting status of
the patients at the time of blood draw, we note that the











Non-White 9 9 1.77
White 57 57 1.93 1.20 (0.57, 2.54) 0.64
Gleason score
5–7 13 13 3.59
8–10 51 51 1.60 1.77 (0.94, 3.34) 0.08
Performance Status
0 31 31 1.97
1–2 35 35 1.70 1.20 (0.74, 1.96) 0.46
Metastatic Volume
Low 31 31 3.53
High 35 35 1.27 2.93 (1.70, 5.05) <0.001
Treatment
ADT 34 34 1.60
ADT + Chemo 31 31 2.29 0.99 (0.60, 1.61) 0.95
Diabetes
No 62 62 1.93
Yes 4 4 0.92 2.28 (0.80, 6.45) 0.12
Age 66 66 1.77 0.99 (0.96, 1.02) 0.67
PSA (ln) 66 66 1.77 1.00 (0.99, 1.01) 0.65
Insulin (ln) 66 66 1.77 0.81 (0.67, 0.98) 0.03
RANK (ln) 66 66 1.77 0.82 (0.60, 1.12) 0.22
IGFBP3 (ln) 66 66 1.77 0.89 (0.52, 1.51) 0.66
IGFBP1 (ln) 66 66 1.77 1.05 (0.87, 1.27) 0.59
IGF I 66 66 1.77 0.85 (0.42, 1.74) 0.66
IGF II 66 66 1.77 0.80 (0.27, 2.42) 0.70
HGF (ln) 66 66 1.77 1.63 (1.06, 2.51) 0.03
OPN 66 66 1.77 1.56 (1.13, 2.15) 0.01
C-peptide (ln) 66 66 1.77 0.62 (0.39, 1.00) 0.05
PD1 (ln) 66 66 1.77 0.82 (0.53, 1.25) 0.35
IL6 (ln) 66 66 1.77 1.26 (0.91, 1.75) 0.17
OPG (ln) 66 66 1.77 0.97 (0.84, 1.11) 0.63
PSA prostate specific antigen, RANK Receptor Activator of Nuclear Factor k B,
IGFBP insulin-like growth factor binding protein, IGF insulin-like growth factor,
HGF hepatocyte growth factor, OPN osteopontin, PD1 Programmed cell death
protein 1, IL6 interleukin-6, OPG Osteoprotegerin
For continuous measures, the HR is based on a one unit difference in
the measurement
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half-life of endogenous insulin secreted by pancreatic beta
cells in response to glucose stimulation is about 4 min
[30], i.e. >99 % of the endogenous insulin is expected to
be degraded after 30 min (i.e. seven half lives). Thus, on a
practical level (e.g. the patient flow at the cancer center
which includes check in, waiting at the lab, followed by
blood draw, which usually takes longer than 30 min), it is
likely that the measured insulin levels reflect the subject’s
individual baseline levels, an assumption further sup-
ported by the corresponding C-Peptide levels in our study.
Fig. 2 Progression-free Survival According to Risk Factors (RFs). (a) Low insulin (i.e. below CART cut-off), (b) high osteopontin (OPN), (c) high
hepatocyte growth factor (HGF) (i.e. above CART cut off), and (d) low C-Peptide (i.e. below the median) each represent a risk factor (RF) for
progression. (e) PFS curves were generated for patients falling in 3 separate risk groups: 0, 1, 2 and 3 RFs. No patients had 4 RF
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Biologically, one plausible explanation for our data is
that hyperinsulinemia cooperates with ADT to suppress
autocrine-paracrine sources of testosterone and this dual
inhibition may delay progression to castration-resistance.
It has previously been shown that pre-existing hyper-
insulinemia (for example with type II diabetes, central
adiposity, and/or dyslipidemia) is associated with re-
duced systemic testosterone levels, likely through sup-
pression of adrenal androgens [15]. We, and others,
have previously shown that the transition from andro-
gen dependence to castration-resistance is accompan-
ied by a shift in testosterone synthesis from gonadal
(endocrine) to non-gonadal sources (autocrine-para-
crine) [31, 32]. Within the bone-tumor microenviron-
ment, adrenal androgenic precursors are converted to
testosterone. Since ADT only blocks endocrine sources of
testosterone, hyperinsulinemia might suppress autocrine-
paracrine sources of testosterone to enhance therapy
benefit. Additional studies will be required to test this
possibility.
Thus, in summary, while our original hypothesis on
the role of insulin was based on an extrapolation of
published data in risk of developing and aggressive-
ness of non-metatstatic prostate cancer, our actual
findings are more in keeping with recent literature re-
garding members of the insulin family hormones and
castration-resistance.
We also sought to develop a discovery platform to
identify other potentially important serum factors impli-
cated in castration-resistant progression. Towards this
goal, we identified elevated (i.e. above the CART cut-off )
levels of OPN and HGF and lower levels of C-Peptide as
individually associated with reduced PFS. HGF, and its
cell surface receptor (aka MET kinase), are well de-
scribed in progression and invasion of several tumor
types, including prostate cancer [33]. Met inhibitors
such as the tyrosine kinase inhibitor cabozantinib are
already in clinical trials for advanced prostate cancer [1]
and recent trials have shown high MET expression is as-
sociated with inferior survival [34]. OPN, a ligand for
CD44, intergrins, and other cell surface receptors, is
implicated in tumor progression [35], and has been
shown recently to correlate with response to chemother-
apy in metastatic CRPC [36], and in a meta-analysis was
significantly associated with survival in several cancers,
including prostate cancer [37]. When we combined all
four risk factors, we obtained a better separation of PFS
based on the patients’ numbers of risk factors. Thus, our
model of risk stratification is based on serum proteins
that mechanistically contribute to the complex biology
of castration-resistant progression.
The available samples for analysis represented only
a subset of the originally recruited patients since this
was a retrospective study and prospective sample col-
lection was not part of the original protocol. The
large number of variables, the cutpoint determination
and variable selection may have resulted in over-
fitting. However, the biomarkers included in the final
model all have reported biologic rationale in the lit-
erature, which somewhat increases the confidence in
their validity for this specific question This work indi-
cates that further study of these markers is warranted.
Taken together, we are reporting that a novel pre-
diction model for patients with metastatic androgen-
dependent prostate cancer who are receiving ADT
may be within reach. The exploratory nature of our
study requires additional independent validation of
biomarkers with robust methods in a larger group of
patients to establish a more reliable risk grouping.
Even so, if confirmed, this model may potentially en-
hance our limited prognostic tools available for this
patient population.
Conclusions
Pretreatment serum insulin, HGF, OPN, and C-peptide
levels can predict PFS in men with mADPC treated with
ADT. Independent validation of this algorithm could pro-
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